(c) 2024 PillSync.com

Rosuvastatin calcium 5 MG Oral Tablet

1 INDICATIONS AND USAGE Rosuvastatin tablets are indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor. As an adjunct to diet to: Reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. Reduce LDL-C and slow the progression of atherosclerosis in adults. Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: primary dysbetalipoproteinemia. Hypertriglyceridemia. Rosuvastatin tablets are an HMG Co-A reductase inhibitor (statin) indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor. As an adjunct to diet to: reduce LDL-C in adults with primary hyperlipidemia. reduce LDL-C and slow the progression of atherosclerosis in adults. reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: primary dysbetalipoproteinemia. Hypertriglyceridemia.

apotex corp.


10 months ago ROUND YELLOW APO ROS 5 Rosuvastatin calcium 5 MG Oral Tablet

ROUND YELLOW APO ROS 5

10 months ago ROUND YELLOW APO ROS 5 Rosuvastatin calcium 5 MG Oral Tablet

APO ROS 5 ROUND YELLOW

16 HOW SUPPLIED/STORAGE AND HANDLING Rosuvastatin tablets, USP are available containing 5 mg, 10 mg, 20 mg or 40 mg of rosuvastatin. 5 mg: yellow, round, biconvex film-coated tablets. Engraved "APO" on one side, "ROS" over "5" on the other side. They are supplied as follows: Bottles of 30 (NDC 60505-4502-3) Bottles of 90 (NDC 60505-4502-9) Unit dose blisters of 100 (NDC 60505-4502-0) 10 mg: pink, round, biconvex film-coated tablets. Engraved "APO" on one side, "ROS" over "10" on the other side. They are supplied as follows: Bottles of 30 (NDC 60505-4503-3) Bottles of 90 (NDC 60505-4503-9) Unit dose blisters of 100 (NDC 60505-4503-0) 20 mg: pink, round, biconvex film-coated tablets. Engraved "APO" on one side, "ROS" over "20" on the other side. They are supplied as follows: Bottles of 30 (NDC 60505-4504-3) Bottles of 90 (NDC 60505-4504-9) Unit dose blisters of 100 (NDC 60505-4504-0) 40 mg: pink, oval, biconvex film-coated tablets. Engraved "APO" on one side, "ROS40" on the other side. They are supplied as follows: Bottles of 30 (NDC 60505-4505-3) Bottles of 90 (NDC 60505-4505-9) Unit dose blisters of 100 (NDC 60505-4505-0) Storage Store at 20ºC to 25ºC (68ºF to 77ºF); excursions permitted from 15ºC to 30ºC (59ºF to 86ºF) [see USP Controlled Room Temperature]. Protect from moisture.


More pills like ROUND APO ROS 5












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site